PBYI

Puma Biotechnology Inc

PBYI.US pumabiotechnology.com
9.17
+0.12 (+1.33%)
USD · NASDAQ
52-week range
4.30
9.74
Trading at 90% of the 52-week range
Market Cap
467.16M
P/E Ratio
17.75
Forward P/E
3.46
Book Value
2.71
Div. Yield
N/A
% Institutions
75.66%
% Insiders
15.28%

1 Year

+102.0%

3 Year

+170.5%

10 Year

-85.6%
Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Company Information

Company Name
Puma Biotechnology Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US74587V1070
CIK: 0001401667
CUSIP: 74587V107
Currency: USD
Full Time Employees: 179
Phone: 424 248 6500
Fiscal Year End: December
IPO Date: Apr 24, 2012
Description:

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Address:

10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024

People

Directors & Officers

Name Title Year Born
Mr. Alan H. Auerbach Founder, Chairman, President, CEO & Secretary 1970
Mr. Maximo F. Nougues CFO & Principal Accounting Officer 1969
Mr. Douglas Hunt B.Sc., FRAPS Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer 1965
Mr. Gordon G. Esplin Chief Accounting Officer 1968
Mr. Mariann Ohanesian Senior Director of Investor Relations NA
Ms. Heather Blaber Senior Vice President of Marketing NA
Mr. Roger L. Storms Senior Vice President of Sales NA
Ms. Pamela Wilson BA Senior Vice President of Clinical Operations NA
Dr. Petra Rietschel Senior Vice President of Clinical Development NA
Mr. Kenneth Wiehe Senior Vice President of Supply Chain & Manufacturing NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 07, 2026 Alan H Auerbach N/A Sale 18.01K $5.88 $105.91K
Jan 07, 2026 Douglas M Hunt N/A Sale 5.01K $5.88 $29.48K
Jan 06, 2026 Alan H Auerbach N/A Sale 16.94K $5.84 $98.92K
Jan 06, 2026 Douglas M Hunt N/A Sale 3.97K $5.84 $23.20K
Nov 11, 2025 Michael Patrick Miller N/A Sale 20.00K $4.86 $97.20K
Jul 18, 2025 Alessandra Cesano N/A Sale 27.00K $3.37 $90.99K
Jul 09, 2025 Alan H Auerbach N/A Sale 21.58K $3.54 $76.39K
Jul 09, 2025 Douglas M Hunt N/A Sale 3.44K $3.54 $12.19K
Jul 08, 2025 Alan H Auerbach N/A Sale 25.59K $3.53 $90.34K
Jul 08, 2025 Douglas M Hunt N/A Sale 4.37K $3.53 $15.44K
Jun 13, 2025 Adrian Senderowicz N/A Sale 27.00K $3.40 $91.80K
Jun 13, 2025 Alessandra Cesano N/A Sale 12.15K $3.40 $41.31K
Jun 13, 2025 Allison Dorval N/A Sale 11.61K $3.40 $39.47K
Jun 13, 2025 Brian M Stuglik N/A Sale 8.10K $3.39 $27.46K
Jun 13, 2025 Jay M Moyes N/A Sale 22.00K $3.40 $74.80K
Jun 13, 2025 Troy Edward Wilson N/A Sale 10.80K $3.40 $36.72K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 3.60M Mar 31, 2026 6.97% $0.00 -1.20%
American Century Companies Inc 2.32M Jun 30, 2026 4.49% $0.01 21.06%
Acadian Asset Management LLC 2.04M Mar 31, 2026 3.96% $0.02 711.34%
Renaissance Technologies Corp 1.94M Mar 31, 2026 3.76% $0.02 -8.54%
Vanguard Capital Management, LLC 1.82M Mar 31, 2026 3.52% $0.00 0.00%
Vanguard Portfolio Management, LLC 1.73M Mar 31, 2026 3.36% $0.00 0.00%
LSV Asset Management 1.62M Jun 30, 2026 3.13% $0.02 36.78%
Dimensional Fund Advisors, Inc. 1.52M Jun 30, 2026 2.94% $0.00 5.70%
O'Shaughnessy Asset Management LLC 1.14M Mar 31, 2026 2.20% $0.04 1.59%
Geode Capital Management, LLC 1.02M Mar 31, 2026 1.97% $0.00 2.31%
State Street Corp 917.59K Mar 31, 2026 1.78% $0.00 4.62%
Kennedy Capital Management Inc 873.25K Jun 30, 2026 1.69% $0.13 -1.84%
AQR Capital Management LLC 800.19K Mar 31, 2026 1.55% $0.00 20.04%
Connor Clark & Lunn Inv Mgmt Ltd 782.80K Mar 31, 2026 1.52% $0.01 -10.57%
Bridgeway Capital Management, LLC 775.34K Mar 31, 2026 1.50% $0.10 0.24%
Comprehensive Portfolio Management, LLC 749.80K Jun 30, 2026 1.45% $0.09 -3.17%
The Goldman Sachs Group Inc 669.72K Mar 31, 2026 1.30% $0.00 -15.65%
Northern Trust Corp 641.75K Mar 31, 2026 1.24% $0.00 4.15%
Millennium Management LLC 602.24K Jun 30, 2026 1.17% $0.00 -59.24%
Arrowstreet Capital Limited Partnership 538.16K Mar 31, 2026 1.04% $0.00 -1.77%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Avantis US Small Cap Value ETF 2.26M 4.38% ▲ 0.11% Aug 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 1.34M 2.60% ▲ 0.00% Jul 31, 2026
3 iShares Russell 2000 ETF 1.16M 2.25% ▼ 0.57% Aug 31, 2026
4 Vanguard Explorer Inv 777.39K 1.51% ▲ 0.00% Jun 30, 2026
5 Vanguard Strategic Equity Inv 540.43K 1.05% ▲ 0.00% Jun 30, 2026
6 Fidelity Small Cap Index 477.95K 0.93% ▲ 12.10% Jun 30, 2026
7 Kennedy Micro Cap 452.53K 0.88% ▼ 12.24% Jun 30, 2026
8 Vanguard Institutional Extnd Mkt Idx Tr 446.90K 0.87% ▲ 0.00% Jul 31, 2026
9 Kennedy Micro Cap Opportunities 366.57K 0.71% ▼ 1.50% Jun 30, 2026
10 iShares Russell 2000 Value ETF 356.35K 0.69% ▼ 0.23% Aug 31, 2026

Financial Highlights

Market Cap: $467.16M
EBITDA: $40.12M
P/E Ratio: $17.75
PEG Ratio: $0.03
Book Value: $2.71
Earnings/Share: $0.51
Profit Margin: 11.55%
Operating Margin: 13.42%
ROA (TTM): 9.81%
ROE (TTM): 21.97%
Revenue (TTM): $231.24M
Revenue/Share (TTM): $4.57
Earnings Growth (YOY): 35.80%
Revenue Growth (YOY): 7.80%

Valuation Metrics

Enterprise Value: $395.63M
Trailing P/E: 17.75
Forward P/E: 3.46

Shares Statistics

Shares Outstanding: 51.62M
Shares Float: 39.62M
% Insiders: 15.28%
% Institutions: 75.66%
Short % Float: 9.46%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$228.37M
Cost of Goods Sold
adjust
$-58.16M
Gross Profit
subtotal
$170.21M
SG&A
adjust
$-71.21M
R&D
adjust
$-62.07M
Operating Income
subtotal
$37.30M
Other / Non-Operating Items
adjust
$-6.19M
Net Income
subtotal
$31.11M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about PBYI.US!